Behavioral Characteristics and Injection Practices Associated with Skin and Soft Tissue Infections among People who Inject Drugs: A Community-Based Observational Study
Restricted accessResearch articleFirst published online January, 2017
Behavioral Characteristics and Injection Practices Associated with Skin and Soft Tissue Infections among People who Inject Drugs: A Community-Based Observational Study
Background: People who inject drugs (PWID) are at increased risk for bacterial skin and soft tissue infections (SSTIs). Although SSTIs pose significant health risks, little is known about their prevalence and characteristics in the population of PWID in the United States. This study investigates whether behavioral factors related to skin and equipment hygiene and tissue-damaging injection practices are associated with recent SSTIs among PWID. Methods: Active PWID were recruited using targeted sampling in San Francisco in 2011–2013. Interviewers collected information on behavioral risk factors of past-month self-reported SSTIs. Inferential analyses used multivariate logistic regression methods (i.e., generalized linear model) to characterize risk factors for past-month SSTIs. Results: The self-reported prevalence of lifetime, past-year, and past-month SSTI was 70%, 29%, and 11%, respectively. Several factors were significantly associated with past-month SSTIs in bivariate analysis, including injecting nonpowder drugs (odds ratio [OR] = 3.57; 95% confidence interval [CI] = 1.23, 10.35; P = .01), needle-licking before injection (OR = 3.36; 95% CI = 1.28, 8.81; P = .01), injecting with someone else's preused syringe/needle (OR = 7.97; 95% CI = 2.46, 25.83; P < .001), being injected by another person (OR = 2.63; 95% CI = 1.02, 6.78; P = .04), infrequent skin cleaning before injection (OR = 2.47; 95% CI = 1.00, 6.10; P = .04), and frequent injections (P = .02). In multivariate analysis, only syringe/needle sharing (adjusted OR = 6.38; 95% CI = 1.90, 21.46) remained statistically significant. Conclusion: SSTIs are common among PWID. These data highlight the importance of clinical and public health screening efforts to reduce SSTIs. Needle exchange programs may be good venues for SSTIs screening and treatment.
Eurosurveillance Editorial Team. EMCDDA publishes 2012 report on the state of the drugs problem in Europe. Euro Surveill.2012;17:20315.
2.
GordonRJ, LowyFD. Bacterial infections in drug users. N Engl J Med.2005;353:1945–1954.
3.
DiNubileMJ, LipskyBA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother.2004;53(Suppl 2):ii37–ii50.
4.
BassettiS, BattegayM. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection.2004;32:163–169.
5.
ParkHY, KimCR, HuhIS, . Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann Dermatol.2013;25:410–416.
6.
RobicsekA, BeaumontJL, PetersonLR. Duration of colonization with methicillin-resistant Staphylococcus aureus. Clin Infect Dis.2009;48:910–913.
7.
Del GiudiceP. Cutaneous complications of intravenous drug abuse. Br J Dermatol.2004;150:1–10.
8.
SpijkermanIJ, van AmeijdenEJ, MientjesGH, CoutinhoRA, van den HoekA. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol.1996;49:1149–1154.
9.
HopeV, KimberJ, VickermanP, HickmanM, NcubeF. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis.2008;8:120.
10.
BadiagaS, RaoultD, BrouquiP. Preventing and controlling emerging and reemerging transmissible diseases in the homeless. Emerg Infect Dis.2008;14:1353–1359.
11.
Lloyd-SmithE, KerrT, HoggRS, LiK, MontanerJS, WoodE. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J.2005;2:24.
12.
Lloyd-SmithE, WoodE, ZhangR, TyndallMW, MontanerJS, KerrT. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health.2008;8:405.
13.
LorvickJ, KralAH, SealK, GeeL, EdlinBR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health.2001;91:46–47.
14.
BinswangerIA, KralAH, BluthenthalRN, RyboldDJ, EdlinBR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis.2000;30:579–581.
15.
PhillipsKT, SteinMD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am J Drug Alcohol Abuse.2010;36:92–97.
16.
PolliniRA, GallardoM, HasanS, . High prevalence of abscesses and self-treatment among injection drug users in Tijuana, Mexico. Int J Infect Dis.2010;14(Suppl 3):e117–e122.
17.
BassettiS, HoffmannM, BucherHC, FluckigerU, BattegayM. Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis.2002;34:711–713.
18.
MurphyEL, DeVitaD, LiuH, . Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis.2001;33:35–40.
19.
PalepuA, TyndallMW, LeonH, . Hospital utilization and costs in a cohort of injection drug users. CMAJ.2001;165:415–420.
20.
VlahovD, SullivanM, AstemborskiJ, NelsonKE. Bacterial infections and skin cleaning prior to injection among intravenous drug users. Public Health Rep.1992;107:595–598.
21.
DwyerR, ToppL, MaherL, . Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend.2009;100:9–16.
22.
FinkDS, LindsaySP, SlymenDJ, KralAH, BluthenthalRN. Abscess and self-treatment among injection drug users at four California syringe exchanges and their surrounding communities. Subst Use Misuse.2013;48:523–531.
23.
SmithME, RobinowitzN, ChaulkP, JohnsonKE. High rates of abscesses and chronic wounds in community-recruited injection drug users and associated risk factors. J Addict Med.2015;9:87–93.
24.
MackenzieAR, LaingRB, DouglasJG, GreavesM, SmithCC. High prevalence of iliofemoral venous thrombosis with severe groin infection among injecting drug users in North East Scotland: successful use of low molecular weight heparin with antibiotics. Postgrad Med J.2000;76:561–565.
25.
SwisherLA, RobertsJR, GlynnMJ. Needle licker's osteomyelitis. Am J Emerg Med.1994;12:343–346.
26.
DeutscherM, PerlmanDC. Why some injection drug users lick their needles: a preliminary survey. Int J Drug Policy.2008;19:342–345.
27.
DahlmanD, HåkanssonA, BjörkmanP, BloméMA, KralAH. Correlates of skin and soft tissue infections in injection drug users in a syringe-exchange program in Malmo, Sweden. Subst Use Misuse.2015;50:1529–1535.
28.
AitkenCK, HiggsP. Severe vein damage caused by Temezepam injecting. Aust N Z J Public Health.2002;26:79.
29.
Barańska-RybakW, BłażewiczI, KakolM, RoterM, NowickiR. Cutaneous manifestations of injectable drug use: hidden secrets. Cutis.2014;93:185–187.
30.
FeeneyGF, GibbsHH. Digit loss following misuse of temazepam. Med J Aust.2002;176:380.
31.
JenkinsonRA, ClarkNC, FryCL, DobbinM. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?Addiction.2005;100:197–205.
32.
PartanenTA, VikatmaaP, TukiainenE, LepäntaloM, VuolaJ. Outcome after injections of crushed tablets in intravenous drug abusers in the Helsinki University Central Hospital. Eur J Vasc Endovasc Surg.2009;37:704–711.
33.
YeoAK, ChanCY, ChiaKH. Complications relating to intravenous buprenorphine abuse: a single institution case series. Ann Acad Med Singapore.2006;35:487–491.
34.
BouquiéR, WainsteinL, PiletP, . Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS ONE.2014;9:e113991.
LankenauSE, KecojevicA, SilvaK. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs (Abingdon Engl).2015;22:35–42.
37.
RosenblumA, ParrinoM, SchnollSH, . Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend.2007;90:64–71.
38.
HakanssonA, MedvedeoA, AnderssonM, BerglundM. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur Addict Res.2007;13:207–215.
39.
WinstockAR, LeaT, SheridanJ. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy.2008;19:450–458.
40.
ImbertB, CohenJ, SimonN. Intravenous abuse of methylphenidate. J Clin Psychopharmacol.2013;33:720–721.
41.
Centers for Disease Control and Prevention (CDC). Soft tissue infections among injection drug users—San Francisco, California, 1996–2000. MMWR Morb Mortal Wkly Rep.2001;50:381–384.
42.
BluthenthalRN, WattersJK. Multimethod research from targeted sampling to HIV risk environments. NIDA Res Monogr.1995;157:212–230.
43.
KralAH, MalekinejadM, VaudreyJ, . Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. J Urban Health.2010;87:839–850.
44.
VittinghoffE, McCullochCE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol.2007;165:710–718.
45.
IBM Corp. IBM SPSS Statistics for Windows. Version 22.0. Armonk, NY: IBM Corp; 2013.
46.
WattersJK, EstiloMJ, ClarkGL, LorvickJ. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA.1994;271:115–120.
47.
JohnsonKM, FibbiM, LangerD, SilvaK, LankenauSE. Prescription drug misuse and risk behaviors among young injection drug users. J Psychoactive Drugs.2013;45:112–121.
48.
RoyE, ArrudaN, BourgoisP. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse.2011;46:1142–1150.
49.
AlyR, MaibachHI, ShinefieldHR. Microbial flora of atopic dermatitis. Arch Dermatol.1977;113:780–782.
50.
WankeI, SkabytskaY, KraftB, PeschelA, BiedermannT, SchittekB. Staphylococcus aureus skin colonization is promoted by barrier disruption and leads to local inflammation. Exp Dermatol.2013;22:153–155.
51.
MorrisonA, ElliottL, GruerL. Injecting-related harm and treatment-seeking behaviour among injecting drug users. Addiction.1997;92:1349–1352.
52.
DarkeS. Self-report among injecting drug users: a review. Drug Alcohol Depend.1998;51:253–63; discussion 267–268.
53.
RouxP, CarrieriMP, KeijzerL, DasguptaN. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug Alcohol Rev.2011;30:287–290.
54.
ZuleWA, BobashevG. High dead-space syringes and the risk of HIV and HCV infection among injecting drug users. Drug Alcohol Depend.2009;100:204–213.
55.
ZuleWA, CrossHE, StoverJ, PretoriusC. Are major reductions in new HIV infections possible with people who inject drugs? The case for low dead-space syringes in highly affected countries. Int J Drug Policy.2013;24:1–7.
56.
PhillipsKT, AltmanJK, CorsiKF, SteinMD. Development of a risk reduction intervention to reduce bacterial and viral infections for injection drug users. Subst Use Misuse.2013;48:54–64.
57.
PhillipsKT, SteinMD, AndersonBJ, CorsiKF. Skin and needle hygiene intervention for injection drug users: results from a randomized, controlled Stage I pilot trial. J Subst Abuse Treat.2012;43:313–321.
